Iron porphyrazines as efficient, catalytic and scalable method to produce chlorine dioxide

US11242248B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11242248-B2
Application numberUS-201916400277-A
CountryUS
Kind codeB2
Filing dateMay 1, 2019
Priority dateAug 23, 2010
Publication dateFeb 8, 2022
Grant dateFeb 8, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods, kits, cartridges, and compounds related to generating chlorine dioxide by exposing ClO 2 − to at least one of an iron porphyrin catalyst or an iron porphyrazine catalyst are described.

First claim

Opening claim text (preview).

What is claimed is: 1. A cartridge comprising a housing and at least one of an iron porphyrin catalyst or an iron porphyrazine catalyst in the housing, wherein the cartridge is adapted to allow reactants to contact the at least one of an iron porphyrin catalyst or an iron porphyrazine catalyst, and the cartridge further comprises at least one of the reactants or a source of ClO 2 − in the housing, and the reactants comprise ClO 2 − . 2. The cartridge of claim 1 , wherein the iron porphyrin catalyst has a structure of formula I: wherein the a is the oxidation state II, III or IV of the Fe and R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting of TM2PyP, TM4PyP, TDMImP, and TDMBImp, which have a structure of formulas II, III, IV, and V, respectively: and at least one of R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, CH 2 —(CH 2 ) n1 —CH 3 where n1=5-20, CH 2 —(CH 2 ) n2 —CH 2 —X where n2=0-20, —CH 2 (CO)—(CH 2 ) n3 —CH 2 —X where n3=0-20, —CH 2 —Ar—X, (CH 2 ) n —X, (CH 2 ) m Ar—X, (CH 2 ) m Ar—Y, (CH 2 ) n —Y, CH 2 CONH—Y; CH 2 COO—Y, CH 2 CO(CH 2 ) P —Y, (OCH 2 CH 2 ) m —Y, (OCH 2 CH 2 ) m —X; Y 2 —X, CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 , —CH 2 CO 2 CH 2 CH 3 , alkyl, CH 2 CH 2 OCH 3 , CH 2 CH 2 OCH 2 CH 2 OCH 3 , (CH 2 ) n —X, (CH 2 ) n —Y, (CH 2 ) n Ar—X, (CH 2 ) n Ar—Y, CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 , CH 2 CO 2 CH 2 CH 3 , (OCH 2 CH 2 ) m —X, (OCH 2 CH 2 ) m —Y, Y 2 —X, or Y 2 C(Z 1 ) 3 ; where Z 1 is CH 2 OCH 2 (CH 2 ) n X, CH 2 OCH 2 (CH 2 ) n Y, or (CH 2 ) n C(O)Y 2 C(Z 2 ) 3 ; Z 2 is CH 2 OCH 2 CH 2 C(O)Y 2 C(Z 4 ) 3 ; Z 4 is CH 2 OCH 2 CH 2 X or (CH 2 ) n C(O)—Y 2 —C(Z 5 ) 3 ; Z 5 is CH 2 OCH 2 CH 2 C(O)Y 2 C(Z 6 ) 3 ; Z 6 is CH 2 OCH 2 CH 2 C(O)O(CH 2 CH 2 O) m CH 2 CH 2 O, (CH 2 ) n OCH 2 C(CH 2 OH) 3 , (CH 2 ) n OCH 2 CH(CH 2 OH) 2 , (CH) n OCH 2 C(CH 2 OH) 2 (CH 3 ), (CH 2 ) n OCH 2 C[CH 2 OCH 2 C(CH 2 OH) 3 ] 3 , (CH 2 ) n OCH 2 C[CH 2 OCH 2 C(CH 2 O[CH 2 CH 2 O] m CH 2 CH 2 OX) 3 , CH 2 CONH—Y, CH 2 CO—Y, or CH 2 CO(CH 2 ) P —Y; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH 2 —Ar—X, (CH 2 ) m Ar—X, or (CH 2 ) m Ar—Y, the X or Y is attached ortho- meta- or para to the —CH 2 — attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl 1 ), CONH 2 , CONH(alkyl 1 ), CON(alkyl 1 ) 2 , CO(CH 2 ) P alkyl 1 , OPO 3 H 2 , PO 3 H 2 , SO 3 H, NH 2 , N(alkyl 1 ) 2 , or N(alkyl 1 ) 3 + , where alkyl 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; Y is OH, (O—CH 2 CH 2 ) m —W 1 , or (CH 2 CH 2 ) m —W 2 , where W 1 is OH or (O—(CH 2 CH 2 ) m OH), and W 2 is O-alkyl; and Y 2 is —(CH 2 ) n O—, —(CH 2 ) n NH—, —(CH) n S—; CH 2 CONH—, CH 2 COO—, or CH 2 CO(CH 2 ) p —; and L 1 and L 2 are, independently absent, halide, oxo, aquo, hydroxo, CN, OPO 3 H, or alcohol. 3. The cartridge of claim 2 , wherein the alkyl is selected from straight-chain or branched-chain alkyl radicals containing from 1 to 22 carbon atoms, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, and eicosyl. 4. The cartridge of claim 2 , wherein R 1 , R 2 , R 3 , and R 4 are TDMBImp. 5. The cartridge of claim 2 , wherein R 1 , R 2 , R 3 , and R 4 are TM2PyP or R 1 , R 2 , R 3 and R 4 are TM4PyP. 6. The cartridge of claim 1 , wherein the iron porphyrazine catalyst has a structure of formula VI: wherein a is the oxidation state II, III or IV of the Fe and each of A 1 , A 2 , A 3 , A 4 , B 1 , B 2 , B 3 , B 4 , C 1 , C 2 , C 3 , C 4 , D 1 , D 2 , D 3 , and D 4 are independently selected from N + —R n , N, C—H, C—X, and C—R n ; when N + —R n is selected, only one in each set of A 1 , B 1 , C 1 , and D 1 ; A 2 , B 2 , C 2 , and D 2 ; A 3 , B 3 , C 3 , and D 3 ; or A 4 , B 4 , C 4 , and D 4 is N + —R n ; when N is selected, only one in each set of A 1 , B 1 , C 1 , and D 1 ; A 2 , B 2 , C 2 , and D 2 ; A 3 , B 3 , C 3 , and D 3 ; or A 4 , B 4 , C 4 , and D 4 is N; each R, is independently selected from the group consisting of H, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, CH 2 —(CH 2 ) n1 —CH 3 where n1=5-20, CH 2 —(CH 2 ) n2 —CH 2 —X where n2=0-20, CH 2 (CO)—(CH 2 ) n3 —CH 2 —X where n3=0-20, CH 2 —Ar—X, (CH 2 ) n —X; (CH 2 ) m Ar—X, (CH 2 ) m Ar—Y, (CH 2 ) n —Y, CH 2 CONH—Y; CH 2 COO—Y, CH 2 CO—Y, CH 2 CO(CH 2 ) P —Y, (OCH 2 CH 2 ) m —Y, (OCH 2 CH 2 ) m —X, Y 2 —X, CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 3 , CH 2 CO 2 CH 2 CH 3 , CH 2 CH 2 OCH 3 , CH 2 CH 2 OCH 2 CH 2 OCH 3 , (CH 2 ) n —Y, (CH 2 ) n Ar—X, (CH 2 ) n Ar—Y, and Y 2 C(Z 1 ) 3 ; Z 1 is CH 2 OCH 2 (CH 2 ) n X, CH 2 OCH 2 (CH 2 ) n Y, or (CH 2 ),C(O)Y 2 C(Z 2 ) 3 ; Z 2 is CH 2 OCH 2 CH 2 C(O)Y 2 C(Z 3 ) 3 ; Z 3 is CH 2 OCH 2 CH 2 X or (CH 2 ) n C(O)—Y 2 —C(Z 4 ) 3 ; Z 4 is CH 2 OCH 2 CH 2 C(O)Y 2 C(Z 5 ) 3 ; and Z 5 is CH 2 OCH 2 CH 2 C(O)O(CH 2 CH 2 O) m CH 2 CH 2 O, (CH 2 ) n OCH 2 C(CH 2 OH) 3 , (CH 2 ) n OCH 2 CH(CH 2 OH) 2 , (CH 2 ) n OCH 2 C(CH 2 OH) 2 (CH 3 ), (CH 2 ) n OCH 2 C[CH 2 OCH 2 C(CH 2 OH) 3 ] 3 , (CH 2 ) n OCH 2 C[CH 2 OCH 2 C(CH 2 O[CH 2 CH 2 O] m CH 2 CH 2 OX) 3 , CH 2 CONH—Y, CH 2 CO—Y, or CH 2 CO(CH 2 ) P —Y; where Ar is substituted or unsubstituted phenyl, substituted or unsubstituted biphenyl, or substituted or unsubstituted naphthyl and when Ar is the phenyl in —CH 2 —Ar—X, (CH 2 ) m Ar—X, or (CH 2 ) m Ar—Y, the X or Y is attached ortho- meta- or para to the —CH 2 — attached to pyridoporphyrazine; n is 1 to 10; m is 1 to 200; p is 1 or 2; X is COOH, COO(alkyl 1 ), CONH 2 , CONH(alkyl 1 ), CON(alkyl 1 ) 2 , CO(CH 2 ) P alkyl 1 , OPO 3 H 2 , PO 3 H 2 , SO 3 H, NH 2 , N(alkyl 1 ) 2 , or N(alkyl 1 ) 3 + , where alkyl 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; Y is OH, (O—CH 2 CH 2 ) m —W 1 , or (CH 2 CH 2 ) m —W 2 ; W 1 is OH or (O—(CH 2 CH 2 ) m OH); W 2 is O-alkyl; and Y 2 is —(CH 2 ) n O—, —(CH 2 ) n NH—, —(CH 2 ) n S—; CH 2 CONH—, CH 2 COO—, or CH 2 CO(CH 2 ) p —; and L 1 and L 2 are independently absent, halide, oxo, aquo, hydroxo, CN, OPO 3 H, or alcohol. 7. The cartridge of claim 6 , wherein in the O-alkyl the alkyl is selected from straight-chain or branched-chain alkyl radicals containing from 1 to 22 carbon atoms, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, and eicosyl. 8. The cartridge of claim 1 , wherein the cartridge comprises the reactants, and the reactants. 9. The cartridge of claim 8 , wherein the ClO 2 − is in the form of at least one substance selected from the group consisting of chlorite salts. 10. The cartridge of claim 8 , wherein the ClO 2 − is in the form of at least one substance selected from the group consisting of sodium chlorite, potassium chlorite, calcium chlorite and magnesium chlorite. 11. The cartridge of claim 8 , wherein the ClO 2 − is mixed with a solid filler. 12. The cartridge of claim 8 , wherein the ClO 2 − is adsorbed on at least one substance selected from the group consisting of clay, silica, alumina and organic polymers.

Assignees

Inventors

Classifications

  • Iron · CPC title

  • with more than one complexing nitrogen atom, e.g. phenanthroline · CPC title

  • C01B11/024Primary

    from chlorites · CPC title

  • with ClO2 or chlorites · CPC title

  • without a metal-carbon linkage · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11242248B2 cover?
Methods, kits, cartridges, and compounds related to generating chlorine dioxide by exposing ClO 2 − to at least one of an iron porphyrin catalyst or an iron porphyrazine catalyst are described.
Who is the assignee on this patent?
Univ Princeton
What technology area does this patent fall under?
Primary CPC classification C01B11/024. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).